WALTHAM, Mass., Jan. 21 /PRNewswire/ -- Boston IVF today announced it will be the first IVF center in the northeast to offer Repromedix's Plan Ahead(TM) test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.
The Plan Ahead Report provides valuable directional information to women planning to have children after their late twenties. Women with faster biological clocks should seek further advice from fertility experts to help ensure that they can have the families they were hoping for.
Dr. Michael M. Alper, Harvard Medical School professor, and the medical director and co-founder of Boston IVF, an internationally renowned fertility treatment center, commented, "As more and more women delay pregnancy until their 30s and even their 40s, there is an urgent need for an accurate early assessment of their fertility. Unfortunately, we see far too many women late in the process when time is of the essence. The fertility field has been waiting for a test like this, and we are delighted to be the first practice to partner with Repromedix in providing this innovative test to women in the greater Boston area."
"The Plan Ahead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer, Repromedix Corp. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The Plan Ahead test offers similar information to the general public via a simple blood test."
Repromedix Corp., the Plan Ahead test co-developer and leading national diagnostic laboratory for fertility testing, chose Boston IVF to be one of a select number of IVF centers to debut the test. Repromedix will expand the Plan Ahead test launch to major markets across the United States throughout 2008.
Plan Ahead is now available to women in the greater Boston area, and women interested in the Plan Ahead test can purchase a test online at http://www.planaheadtest.com/us or at Boston IVF, where they can also have their blood drawn. The blood sample is sent to Repromedix, whose lab performs the advanced testing and submits the report and recommendations to the patient's physician. The cost of the Plan Ahead test is $350.
Women interested in learning more about Plan Ahead, should visit: http://www.planaheadtest.com/us.
About Boston IVF (http://www.bostonivf.com)
Established in 1986, Boston IVF is one of America's most successful fertility centers. Using a team approach to meet every aspect of patients' needs, Boston IVF is committed to giving everyone the chance to build a family. Boston IVF provides patients with unparalleled medical care and the best experience with the expertise of premier doctors and professional staff, who are affiliated with Harvard Medical School. It is world renowned for its highly successful and innovative infertility treatments, highest quality service, state-of-the-art methods, ongoing scientific research, and on-site complementary healthcare at its Domar Center. Boston IVF has convenient locations in Waltham, Mass., Brookline, Mass., and Quincy, Mass., and its doctors see patients at leading hospitals throughout Mass. and Maine.
About Repromedix (http://www.repromedix.com)
Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.
Media contact: Julie Dennehy
508-533-8311 or firstname.lastname@example.org
CONTACT: Julie Dennehy, +1-508-533-8311, email@example.com, for
Web site: http://www.repromedix.com/